CA2934660C - Production d'anticorps ex vivo - Google Patents

Production d'anticorps ex vivo Download PDF

Info

Publication number
CA2934660C
CA2934660C CA2934660A CA2934660A CA2934660C CA 2934660 C CA2934660 C CA 2934660C CA 2934660 A CA2934660 A CA 2934660A CA 2934660 A CA2934660 A CA 2934660A CA 2934660 C CA2934660 C CA 2934660C
Authority
CA
Canada
Prior art keywords
rabbit
cell
nucleic acid
cells
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2934660A
Other languages
English (en)
Other versions
CA2934660A1 (fr
Inventor
Paula Maria Wilhelmina Van Helden
Mark Jeroen KWAKKENBOS
Hergen Spits
Tim Beaumont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kling Biotherapeutics BV
Original Assignee
Kling Biotherapeutics BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kling Biotherapeutics BV filed Critical Kling Biotherapeutics BV
Publication of CA2934660A1 publication Critical patent/CA2934660A1/fr
Application granted granted Critical
Publication of CA2934660C publication Critical patent/CA2934660C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)

Abstract

La présente invention concerne des moyens et des méthodes pour produire des cultures de cellules B ex vivo avec un temps de doublement court.
CA2934660A 2013-12-24 2014-12-24 Production d'anticorps ex vivo Active CA2934660C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13199584 2013-12-24
EP13199584.7 2013-12-24
PCT/NL2014/050908 WO2015099534A1 (fr) 2013-12-24 2014-12-24 Production d'anticorps ex vivo

Publications (2)

Publication Number Publication Date
CA2934660A1 CA2934660A1 (fr) 2015-07-02
CA2934660C true CA2934660C (fr) 2023-03-14

Family

ID=49885067

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934660A Active CA2934660C (fr) 2013-12-24 2014-12-24 Production d'anticorps ex vivo

Country Status (15)

Country Link
US (3) US20170009205A1 (fr)
EP (2) EP3087177B1 (fr)
JP (1) JP6832705B2 (fr)
CN (1) CN106029873A (fr)
AU (1) AU2014370516B9 (fr)
BR (1) BR112016014881B1 (fr)
CA (1) CA2934660C (fr)
DK (1) DK3087177T3 (fr)
EA (1) EA201691112A1 (fr)
ES (1) ES2927905T3 (fr)
HU (1) HUE060145T2 (fr)
IL (1) IL246409B (fr)
MX (1) MX386674B (fr)
SG (1) SG11201605126YA (fr)
WO (1) WO2015099534A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2626671T3 (es) * 2010-12-02 2017-07-25 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
CN116554353B (zh) 2023-04-28 2024-05-03 北京奇迈永华生物科技有限公司 一种假病毒高效感染人nk细胞及其他免疫细胞的方法
CN118459577B (zh) * 2024-07-09 2024-11-12 浙江康佰裕生物科技有限公司 逆转录包膜蛋白GALV env蛋白及其抗体的制备

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1499736T3 (da) * 2002-04-26 2009-06-08 Inst Nat Sante Rech Med Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorer
US7919672B2 (en) 2005-08-03 2011-04-05 Therapeutic Human Polyclonals, Inc. Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin
DK1974017T4 (da) * 2005-12-09 2023-09-25 Academisch Medisch Centrum Bij De Univ Van Amsterdam Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
ES2434256T3 (es) * 2010-05-28 2013-12-16 F. Hoffmann-La Roche Ag Método de cultivo de células B individuales y producción de anticuerpos específicos
ES2626671T3 (es) * 2010-12-02 2017-07-25 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
KR102069394B1 (ko) * 2011-11-23 2020-01-22 에프. 호프만-라 로슈 아게 Ｃｄ40ｌ 발현 포유류 세포 및 그의 용도
WO2014109696A1 (fr) * 2013-01-10 2014-07-17 Alf Grandien Procédé d'immortalisation de lymphocytes b et ses utilisations
WO2015115892A1 (fr) * 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Moyens et procédés de production d'anticorps stables

Also Published As

Publication number Publication date
ES2927905T3 (es) 2022-11-11
US20170009205A1 (en) 2017-01-12
CN106029873A (zh) 2016-10-12
DK3087177T3 (da) 2022-10-03
NZ722156A (en) 2021-08-27
EA201691112A1 (ru) 2017-01-30
EP3087177B1 (fr) 2022-09-14
EP4141108A1 (fr) 2023-03-01
EP3087177A1 (fr) 2016-11-02
WO2015099534A1 (fr) 2015-07-02
IL246409B (en) 2022-01-01
BR112016014881B1 (pt) 2023-03-28
JP2017500052A (ja) 2017-01-05
US20200149007A1 (en) 2020-05-14
IL246409A0 (en) 2016-08-31
MX2016008345A (es) 2017-02-08
AU2014370516B2 (en) 2021-03-11
US20240425566A1 (en) 2024-12-26
AU2014370516A1 (en) 2016-07-07
US12084681B2 (en) 2024-09-10
AU2014370516B9 (en) 2021-07-29
MX386674B (es) 2025-03-19
HUE060145T2 (hu) 2023-02-28
BR112016014881A8 (pt) 2020-06-09
CA2934660A1 (fr) 2015-07-02
JP6832705B2 (ja) 2021-02-24
SG11201605126YA (en) 2016-07-28
BR112016014881A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
US20240425566A1 (en) Ex vivo antibody production
AU2014202709B2 (en) Means and methods for influencing the stability of antibody producing cells
EP2797951B1 (fr) Procédé d'isolation d'anticorps humains
AU2019275479B2 (en) Chimeric antigen receptors with modified linker domains and uses thereof
US20240245771A1 (en) Fully human antibody for human b7h3, chimeric antigen receptor and uses thereof
CN113195527A (zh) Tcr和肽
WO2014109696A1 (fr) Procédé d'immortalisation de lymphocytes b et ses utilisations
WO2018205917A1 (fr) Nouveau procédé de production d'anticorps
JP2017516496A5 (fr)
US20180369282A1 (en) Gene-modified lymphocytes expressing chimeric antigen receptor in which production of inflammatory cytokines is inhibited
NZ722156B2 (en) Ex vivo antibody production
EA044991B1 (ru) Образование антител ex vivo
US20110171688A1 (en) Method of providing immunoglobulin secreting b lymphocytes and human antibodies
CN120239745B (zh) 永生化细胞的制造方法
CN117136199A (zh) 靶向bcma的嵌合抗原受体及其应用
CN112608902A (zh) 一种第四代car-t细胞及其应用
CA3275321A1 (fr) Procédé de production d'une cellule immortalisée
EP3284819A1 (fr) Procédé pour la génération d'hybridome de lymphocytes t pour le clonage et l'analyse de récepteurs utilisant des glycoprotéines de fusion du virus de la rougeole par génie génétique
JP2025526827A (ja) モノクローナル抗体の単離
Bhattacharya et al. Regulation of Ig class switch recombination by NF-kB: retroviral expression of RelB in activated B cells inhibits switching to IgG1, but not to IgE

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191120

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241216

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241216

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251215

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251215